Clinical trial
Teriflunomide (Aubagio) Effects on Cognitive and Vocational Outcomes, as Related to Neurodegeneration in Multiple Sclerosis: A Prospective, Observational, Single-blinded Study.
NCT02651545 is registered in ClinicalTrials.gov with State University of New York at Buffalo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Teriflunomide (Aubagio) Effects on Cognitive and Vocational Outcomes, as Related to Neurodegeneration in Multiple Sclerosis: A Prospective, Observational, Single-blinded Study.
- Lead sponsor
- State University of New York at Buffalo
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 28, 2014
- Completion date
- November 30, 2020
- Enrollment
- 60 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.